Recent Developments in the Antibody Drug Market

In January 2022, Amgen and AstraZeneca received FDA approval for TEZSPIRE (tezepelumab-ekko) to treat severe asthma, marking a significant expansion in their product portfolio and promising strong revenue potential.

In November 2020, Regeneron received Emergency Use Authorization (EUA) from the US FDA for its antibody cocktail, casirivimab and imdevimab, to treat COVID-19. This approval has significantly boosted the company’s market share and revenue.

Roche made strides in sequencing technology with the launch of the AVENIO Edge System in December 2021. This system offers an automated, integrated approach to sequencing library preparation and target enrichment, ensuring high-quality, reliable results.

In November 2021, Roche introduced the cobas® 5800 System in CE-marked countries, enhancing molecular laboratory testing to aid in rapid, precise treatment decisions.

Roche also unveiled its automated digital pathology algorithms, uPath HER2 (4B5) and uPath Dual ISH image analysis, in January 2021 to help pathologists diagnose breast cancer more accurately and efficiently. These AI-powered tools assist in identifying the best treatment strategies, particularly for patients with HER2 gene mutations, found in up to 20% of global breast cancer cases.

Amgen launched Amgevita, a biosimilar to adalimumab, in Europe in October 2018, further expanding its portfolio.

In December 2019, CARsgen Therapeutics received IND approval in China for its AB011 humanized monoclonal antibody, aimed at treating pancreatic and gastric adenocarcinoma.